



THE AD HOC GROUP FOR MEDICAL RESEARCH

July 2, 2020

The Honorable Diana DeGette
U.S. House of Representatives
Washington, DC 20515

The Honorable Fred Upton
U.S. House of Representatives
Washington, DC 20515

The Honorable Eddie Bernice Johnson
U.S. House of Representatives
Washington, DC 20515

The Honorable Frank Lucas
U.S. House of Representatives
Washington, DC 20515

The Honorable Anna Eshoo
U.S. House of Representatives
Washington, DC 20515

The Honorable Anthony Gonzalez
U.S. House of Representatives
Washington, DC 20515

Dear Representatives DeGette, Upton, Johnson, Lucas, Eshoo, and Gonzalez:

On behalf of the Ad Hoc Group for Medical Research, thank you for your continued efforts to respond to COVID-19 through the introduction of the Research Investment to Secure the Economy (RISE) Act, authorizing emergency relief funds for federal science agencies, including the National Institutes of Health (NIH). This emergency supplemental funding is critical to supporting the progress of biomedical research to improve the health of all Americans.

The Ad Hoc Group for Medical Research is a coalition of over 330 patient and voluntary health groups, medical and scientific societies, academic and research organizations, and industry that support enhancing the federal investment in the biomedical, behavioral, and population-based research conducted and supported by the NIH.

The Ad Hoc Group is pleased to endorse the RISE Act, which would offer an important first step in mitigating COVID-19 related disruptions through \$10 billion in critical support to NIH-funded trainees, technicians, early-stage investigators, and established investigators who face incredible hurdles to career advancement and maintaining momentum toward better prevention, treatments, diagnostics, and cures for thousands of devastating conditions in an increasingly competitive global research environment. [The Ad Hoc Group previously described the effect of COVID-19 on medical research](#), noting an urgent need to respond to the unique challenges on the biomedical research community resulting from rapid lab closures and emerging challenges as labs reopen and pre-pandemic research ramps back up. The associated expenses will only grow as research resumes, and without federal support to offset these costs, we risk delaying our progress on the wide array of science supported by NIH.

Thank you again for your leadership and support of the country's federally funded research workforce, including medical research supported by NIH. We look forward to continuing to work with you to secure this critical relief and in support of our country's research workforce.

Sincerely,

A handwritten signature in black ink that reads 'Tannaz Rasouli'.

Tannaz Rasouli
Executive Director